ArticleTransboundary and emerging diseases2025
A Virulent Systemic Feline Calicivirus Strain Isolated in China Could Produce Broadly Neutralizing Antibodies Against Multiple Strains.
Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A novel replication-deficient feline herpesvirus type 1 vector-based vaccine provides strong immune protection in cats.Journal of virology · 2026Article
- Feline calicivirus VP1-based mRNA vaccine protects cats against FCV challenge.Virologica Sinica · 2026Article
- Sustained circulation of genotype I and the first whole-genome sequencing of feline calicivirus in Turkish cats.BMC veterinary research · 2026Article
- A Virulent Systemic Feline Calicivirus Strain Isolated in China Could Produce Broadly Neutralizing Antibodies Against Multiple Strains.Transboundary and emerging diseases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Feline calicivirus (FCV) is a significant pathogen in cats, with sporadic outbreaks of infections with virulent systemic (VS-FCV) strains causing significant health problems. Nineteen FCV strains were isolated and identified in China from 2021 to 2022. The nucleotide and amino acid phylogenetic analysis of the VP1 gene showed that 16 strains were GI genotype and three strains were GII genotype. HBDL2 strain was further found to be in the same clade as the reported VS-FCV SH/2014 strain, with 87.1% nucleotide sequence identity and 93.0% amino acid sequence identity. However, given that phylogenetic and homology analysis alone is insufficient to predict virulence, the pathogenic potential of HBDL2 was subsequently assessed through experimental infection in cats. The results revealed that HBDL2 was able to cause systemic clinical signs and caused severe tracheal and lung damage, with a similar characterization as the VS-FCV strain. Serum neutralization assays confirmed that HBDL2 elicited broad-spectrum neutralizing antibodies in cats against multiple FCV strains, including diverse GI and GII genotypes. Notably, neutralizing antibody titers against the VS-FCV strains were elevated. Additionally, we established an infectious clone of HBDL2 as a critical technical tool. These findings indicate that the HBDL2 strain holds promise for use in vaccine development against FCV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.